CG Oncology jumps as UBS hikes target to $90 ahead of key Phase 3 readout
CG Oncology (CGON) is up 4.84% to $67.02 as buyers react to a fresh wave of bullish analyst price-target increases tied to upcoming Phase 3 PIVOT-006 topline data expected in the first half of 2026. The most recent catalyst is UBS lifting its target to $90 from $60 while reiterating a Buy rating.
1) What’s moving the stock
CG Oncology shares are rising as investors respond to renewed analyst optimism following a high-profile price-target increase. UBS raised its price target on CG Oncology to $90 from $60 while keeping a Buy rating, framing the setup around expected topline results in the first half of 2026 from the company’s Phase 3 PIVOT-006 trial evaluating cretostimogene grenadenorepvec in intermediate-risk non-muscle invasive bladder cancer. (ng.investing.com)
2) Why the timing matters
The move comes with attention intensifying on the company’s near-term clinical catalyst calendar. PIVOT-006 is positioned as an important value driver because the readout is expected in 1H 2026, and recent analyst notes have pointed to the potential market size and the lack of durable long-term disease control with current intermediate-risk treatment approaches. (ng.investing.com)
3) Additional backdrop investors are watching
Beyond PIVOT-006, investors have been tracking new data disclosures and the broader NMIBC program progress. Recent scientific materials tied to BOND-003 Cohort P describe topline results and safety observations for cretostimogene in a high-risk, papillary-only BCG-unresponsive NMIBC cohort, reinforcing the narrative that the platform may be well tolerated while longer follow-up continues. (cgoncology.com)
4) What to watch next
Near-term trading in CGON is likely to remain sensitive to (1) further changes in Wall Street targets and positioning ahead of the PIVOT-006 readout, and (2) any incremental updates on the company’s regulatory and clinical development timeline. Investors will be watching for confirmation of timing, trial execution signals, and any additional clinical disclosures that refine expectations going into the first-half 2026 topline catalyst. (ng.investing.com)